Drug Profile
LP 100
Latest Information Update: 08 Aug 2003
Price :
$50
*
At a glance
- Originator Lapid Pharmaceuticals
- Class Antihyperglycaemics
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 08 Aug 2003 No development reported - Preclinical for Type-1 diabetes mellitus in Israel (PO)
- 08 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in Israel (PO)
- 18 Jan 2001 Preclinical development for Type-1 diabetes mellitus in Israel (PO)